Insilico Moves Rentosertib Into Phase III as First Fully AI Originated Drug at That Stage

A milestone with a narrow definition

Drug discovery headlines often claim "AI designed" molecules when only one step used machine learning. Insilico Medicine draws a sharper line: rentosertib is the first program where generative AI both identified the biological target and designed the clinical candidate now entering Phase III, according to the company's July 7 announcement. No AI originated drug has won regulatory approval yet, so the distinction is about stage, not proof of market success.

Clinical signal so far

The Phase IIa GENESIS IPF study, published in Nature Medicine, enrolled 71 patients across 15 sites in China. In the 60 milligram once daily arm, mean forced vital capacity improved by 98.4 milliliters over 12 weeks versus a 20.3 milliliter decline on placebo. Forced vital capacity is the functional readout regulators watch closely in idiopathic pulmonary fibrosis because it tracks how much air patients can still move.

The new Phase III trial expands to 320 patients across 47 centers, dosing for 52 weeks with annual FVC decline as the primary endpoint. Professor Zuojun Xu of Peking Union Medical College Hospital leads the study.

What success would prove

If rentosertib hits its pivotal endpoint, it would validate Insilico's end to end pipeline: target discovery, generative chemistry, and iterative design loops that compress early discovery timelines. If it misses, skeptics will argue the Phase IIa cohort was too small or too short to predict payer relevant outcomes.

Either way the trial is the first time a generative AI born molecule faces the scale and duration regulators demand before approval.

Industry context

Large pharma partners continue to option AI surfaced targets while keeping most clinical risk on their own balance sheets. Insilico's bet is that owning the molecule through Phase III demonstrates capability, not just software licensing.

Sources

Insilico Medicine press release, July 7, 2026<br />Nature Medicine GENESIS IPF Phase IIa publication, 2025